KINDERHOOK, N.Y. & SAN DIEGO--(BUSINESS WIRE)--Aug. 23, 2006--American Bio Medica Corporation (NASDAQ: ABMC), a global provider of immunoassay diagnostic test kits, and Nanogen, Inc. (NASDAQ: NGEN), a developer of advanced diagnostic products, announced today that they have entered into a supply agreement in which ABMC will sell its rapid drugs of abuse (DOA) tests to Nanogen. Nanogen will market the tests, under their own Tox STATus(TM) brand name, to customers in hospital- related markets using its existing sales force and distribution network.
